Amgen's cholesterol drug shows positive effect in cardiovascular outcomes study – Pharmaceutical Business Review
U.S. News & World Report |
Amgen’s cholesterol drug shows positive effect in cardiovascular outcomes study
Pharmaceutical Business Review Amgen’s cholesterol drug Repatha (evolocumab) has showed positive effect in a 27,564-patient cardiovascular outcomes study. The trial demonstrated that Repatha has maximum reduced low-density lipoprotein cholesterol (LDL-C) levels, helping to … AMGN On Watch, GALE Reports Positive Data, EBS Secures BARDA Contract Cholesterol drug cuts heart risks, spurs new debate on cost New drug appears to cut cholesterol significantly |
Powered by WPeMatico